Riskpilot← Back to searchSign inGet full accessCanaDan Bio ApS
APSActiveCVR 40896813Skjulhøj Allé 47Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2019— employees
Revenue 2025
DKK -1K
-35% vs 2024
EBITDA margin
100.0%
+35% vs 2024
Equity ratio
3.6%
Financial strength
Net profit 2025
DKK 4K
+26% vs 2024
| Revenue | DKK -1K | -35% |
| EBITDA | DKK -1K | +35% |
| Net profit | DKK 4K | +26% |
| Total assets | DKK 773K | +5% |
| Equity | DKK 28K | +18% |
| Employees | — | — |
Legal name
CanaDan Bio ApS
CVR number
40896813
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29. oktober 2019
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er engroshandel med medicinalvarer og medicinske artikler, fremstilling af farmaceutiske præparater samt aktiviteter indenfor nutraceutisk industri og relaterede aktiviteter.
Address
Skjulhøj Allé 47
Email
lll@megapol.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | -1 | -2 | -1 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 0 | -23 | -47 | -3 | -1 | -2 | -1 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | -23 | -47 | -3 | -1 | -2 | -1 |
| Net financials | -0 | -8 | 33 | 11 | 12 | 7 | 7 |
| Profit before tax | -0 | -31 | -14 | 8 | 11 | 4 | 6 |
| Tax | -0 | -7 | -3 | 2 | 2 | 1 | 1 |
| Net profit | -0 | -24 | -11 | 6 | 9 | 3 | 4 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 363 | 312 | 493 | 676 | 705 | 736 | 773 |
| Equity | 40 | 16 | 5 | 11 | 20 | 24 | 28 |
| Long-term debt | 323 | 296 | 487 | 665 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 685 | 712 | 745 |
| Total debt | 323 | 296 | 487 | 665 | 685 | 712 | 745 |
EBITDA margin
-139500.0%
This company
15.8%
Market median
-883011% vs market
20192025
Equity ratio
3.6%
This company
38.2%
Market median
-91% vs market
20192025
Return on equity
15.6%
This company
18.4%
Market median
+15% vs market
20192025
Net profit margin
437200.0%
This company
8.1%
Market median
+5397431% vs market
20192025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20192025
Debt / equity
26.53×
This company
0.62×
Market median
-4179% vs market
20192025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-10-29 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
Ll Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Megapol ApS | Company | 90.0% | 90.0% | 2019 |
PYTHOR ApS | Company | 10.0% | 10.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PYTHOR ApS
CanaDan Bio ApS Board members of CanaDan Bio ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lionel le Lay | Chief Executive Officer | 0 companies |